Bristol Myers Squibb reported positive interim Phase 1 data for its CAR T-cell therapy, zola-cel, in multiple sclerosis patients, showing sustained disease control and disability improvement. This news is a significant positive for BMS, highlighting potential for a new blockbuster drug in a challenging disease area, but safety concerns remain.
Bristol Myers Squibb announced interim Phase 1 results for its CAR T-cell therapy, zola-cel, for multiple sclerosis. The data showed all 60 patients at the second dose level remained off disease-modifying therapies, and 92% of progressive MS patients had stable or improved disability with no new MRI activity. This is highly significant as it suggests a potential breakthrough in treating MS, particularly the progressive forms which have limited effective treatments. The primary affected party is BMY, which could see substantial long-term revenue if zola-cel progresses through trials and gains approval. Short-term, this could boost investor confidence in BMY's pipeline. However, the reported safety data, including cytokine release syndrome in 42.4% and neurotoxicity in 7.6%, plus a fatal case of septic pneumonia post-cutoff, present a key risk that could temper enthusiasm and require careful monitoring in future trials.